GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (FRA:C4X) » Definitions » Short Percentage of Float

Valerio Therapeutics (FRA:C4X) Short Percentage of Float


View and export this data going back to . Start your Free Trial

What is Valerio Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Valerio Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Valerio Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Valerio Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Valerio Therapeutics's Short Percentage of Float falls into.


Valerio Therapeutics (FRA:C4X) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Valerio Therapeutics (FRA:C4X) » Definitions » Short Percentage of Float
Comparable Companies
XPAR:ALPAT XPAR:ALCOX XPAR:PHXM XPAR:ALACT XPAR:ALNFL XPAR:ALTHX XPAR:ALTME XPAR:ALINT XPAR:ALMDP XPAR:ALDVI OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
ALVIO:France
Address
49 Boulevard du General, Martial Valin, Paris, FRA, 75015
Website
https://www.valeriotx.com
Valerio Therapeutics is a clinical-stage biotechnology company designing and developing novel oncology drugs targeting tumor DNA repair functions. Its therapeutic strategy focuses on fighting tumor resistance to treatments, which poses ever-greater therapeutic challenges, especially in aggressive or rare cancers. its approach is based upon unique mechanisms of action on DNA Damage Response. The company focuses on bringing first-in-class and disruptive compounds from preclinical research to proof-of-concept in man in cancer indications with high unmet needs.

Valerio Therapeutics (FRA:C4X) Headlines

No Headlines